Canopy Biotech develops antigen‑drug conjugates (AgDCs), a biologic platform that selectively eliminates pathogenic autoantibodies and autoreactive B‑cells while preserving normal immune function. By linking disease‑specific antigens to therapeutic payloads, their non‑immunosuppressive therapies aim to provide disease‑modifying, potentially curative treatment for antibody‑mediated autoimmune conditions such as myasthenia gravis.
Funding
Funding not disclosed
Founders
Product
Problem
Antibody-mediated autoimmune diseases are currently treated with broad immunosuppressive drugs that are non‑specific, do not cure the underlying condition, and can cause significant side effects.
Solution
Canopy Biotech is developing antigen‑drug conjugates (AgDCs), a novel class of biologics designed to selectively eliminate pathogenic autoantibodies and autoreactive B‑cells while preserving normal immune function. By coupling a disease‑specific antigen to a therapeutic payload, AgDCs target only the cells responsible for the autoimmune response, offering a non‑immunosuppressive and potentially curative approach. The platform leverages precise antigen selection and controlled drug delivery to achieve high specificity and minimize off‑target effects. Canopy’s pipeline focuses on antibody‑mediated conditions such as myasthenia gravis, with the goal of delivering disease‑modifying therapies that reduce reliance on chronic immunosuppression.
Target Audience
Primary customers are pharmaceutical companies and biotech partners developing therapies for antibody‑mediated autoimmune diseases, as well as clinical researchers seeking disease‑modifying treatment options.
Features
- Antigen‑drug conjugate architecture that binds disease‑specific autoantibodies for targeted cell depletion
- Payloads designed to induce apoptosis of autoreactive B‑cells without affecting protective immune cells
- Modular platform enabling rapid adaptation to multiple antibody‑mediated autoimmune indications
- Preclinical data supporting selective elimination of pathogenic antibodies while maintaining overall immunity
- Scalable manufacturing process based on established biologics production techniques